Notícias

BBIB, BGSI and CLCGY have been added to the Zacks Rank #5 (Strong Sell) List on June 30, 2026.

LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.

Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

The pharma company plans to pause or terminate investment in most of Apellis’ legacy research programmes.

Shares of biotech company Biogen (NASDAQ:BIIB) jumped 5.6% in the afternoon session after investors continued to cheer a string of growth signals, including the $1 billion purchase of RayThera Inc., an FDA Breakthrough Therapy tag for its drug candidate Salanersen, and a recent analyst upgrade.

Lilly, AbbVie and J&J extend winning streaks.

Biogen is betting on Leqembi, Skyclarys and Zurzuvae to offset declining legacy drug sales, but replacing lost revenues may take time.

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q1 therapeutics earnings season.

Biogen Stock Performance Snapshot Biogen (BIIB) has drawn investor attention after a recent move in its share price, with the stock closing at US$196.58. That level sits against a backdrop of mixed short and longer term returns. See our latest analysis for Biogen. Short term momentum for Biogen looks softer, with the 1 day and 7 day share price returns both slightly negative, while the 1 month and year to date share price returns remain positive and the 1 year total shareholder return is...

The proposed acquisition will add anti-inflammatory candidates to Biogen, including RayThera’s lead asset.

The proposed acquisition will add anti-inflammatory candidates to Biogen, including RayThera’s lead asset.

Healthcare stocks fell Thursday afternoon with the NYSE Healthcare Index decreasing 0.9% and the Sta

BIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could expand its immunology pipeline and future growth.

The deal adds multiple small-molecule anti-inflammatory drug candidates to Biogen's pipeline, with the lead asset set to begin human trials this summer

The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents Raythera secured provide important clues.

Biogen (BIIB) agreed to acquire private biotechnology company RayThera in a deal worth up to $1 bill

The deal includes an upfront payment plus milestone payments tied primarily to clinical and regulatory successes.

By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) said it nominated ACU301 and ACU401, two candidates in its Enhanced Brain Delivery program, to treat Alzheimer’s Disease. The nomination comes after the company exercised its option with JCR Pharmaceuticals as part of a previously signed agreement, it stated. Register for our weekly newsletter HERE “We are […] The post Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease appeared first on ExecEdge.

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.

Denali Therapeutics Inc. (NASDAQ:DNLI) is one of the 10 best AI driven biotech stocks to invest in. On May 22, Denali Therapeutics Inc. (NASDAQ:DNLI) halted its joint work with Biogen Inc. (NASDAQ:BIIB), around the development of BIIB122 for idiopathic Parkinson’s disease. The decision came after topline results from the Phase 2b LUMA trial showed that […]

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Biogen has recently outperformed its industry peers, and analysts remain reasonably upbeat about the stock’s prospects.

In early June 2026, Biogen reported that the FDA granted Breakthrough Therapy Designation to its investigational SMA treatment salanersen, while also, alongside UCB, presenting additional positive Phase 3 data for lupus candidate dapirolizumab pegol at the EULAR 2026 Congress. Together, these developments highlight Biogen’s expanding late-stage pipeline in severe neuromuscular and autoimmune diseases, with salanersen’s once-yearly dosing and dapirolizumab pegol’s steroid-sparing potential...

Biogen (BIIB) is back in focus after the FDA granted Breakthrough Therapy Designation to its spinal muscular atrophy candidate salanersen, while fresh Phase 3 lupus data with partner UCB highlighted dapirolizumab pegol’s clinical profile. See our latest analysis for Biogen. Biogen’s recent FDA breakthrough designation for salanersen and fresh lupus data arrive as the share price trades at US$196.45, with a 90-day share price return of 6.26% and a 1-year total shareholder return of 50.70%,...

Biogen's Salanersen secures FDA Breakthrough Therapy designation for SMA after phase Ib data showed motor gains and supports once-yearly dosing.

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

OCGN is advancing gene-agnostic eye therapies across retinal diseases, with key trial data and regulatory milestones approaching in 2026 and 2027.

The drug industry has been working on how to shuttle drugs through the blood-brain barrier, and the results will become apparent this year.

Biogen and Denali Therapeutics have discontinued development of BIIB122 for early-stage Parkinson's disease. The decision follows Phase 2b LUMA trial results, where BIIB122 did not meet efficacy endpoints. The outcome affects Biogen's efforts in neurodegenerative diseases and LRRK2 inhibitor research. For investors tracking NasdaqGS:BIIB, the update comes with the stock trading at $192.23. The shares are up 46.6% over the past year but down 36.4% over three years and down 51.4% over five...

In May 2026, COMPASS Pathways plc elected Kathleen Tregoning to its Board of Directors, with plans for her to join the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee, alongside issuing new option grants to multiple directors including Tregoning. Tregoning’s background in corporate affairs, commercial strategy and late-stage biotech scaling at Cerevel Therapeutics, Sanofi and Biogen introduces additional commercialization and policy...